GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 13, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.

Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity account as of December 31, 2024:

• 207,500 shares
• €353,960.14

During the second half of 2024, total trading was:

• On the buy side: 2,075,591 shares for a total amount of €8,893,798.52
• On the sell side: 1,999,091 shares for a total amount of €8,546,873.15

During this same period, the number of trades were:

• On the buy side: 2,752
• On the sell side: 2,582

As a reminder, upon signing of the contract, the following resources appeared on the liquidity account:

• 27, 911 shares
• €769,849.43

ABOUT GENFIT

GENFIT is a late-stage biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT has built up a diversified and rapidly expanding R&D portfolio of programs at various stages of development. The Company focuses on Acute-on-Chronic Liver Failure (ACLF). Its ACLF franchise includes five assets under development: VS-01, NTZ, SRT-015, CLM-022 and VS-02-HE, based on complementary mechanisms of action using different routes of administration. Other assets target other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorder (UCD) and organic acidemia (OA). GENFIT's expertise in the development of high-potential molecules from early to advanced stages, and in pre-commercialization, was demonstrated in the accelerated approval of Iqirvo® (elafibranor¹) by the U.S. Food and Drug Administration, the European Medicines Agency and the Medicines and Healthcare Regulatory Agency in the UK for Primary Biliary Cholangitis (PBC). Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® in Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis) and TS-01 focusing on blood ammonia levels. GENFIT is headquartered in Lille, France and has offices in Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). The Company is listed on the Nasdaq Global Select Market and on the Euronext regulated market in Paris, Compartment B (Nasdaq and Euronext: GNFT). In 2021, Ipsen became one of GENFIT's largest shareholders, acquiring an 8% stake in the Company's capital. www.genfit.com

FORWARD LOOKING STATEMENTS
This press release contains certain forward-looking statements with respect to GENFIT, including those within the meaning of the Private Securities Litigation Reform Act of 1995, in relation to GENFIT’s research and development programs. The use of certain words, including "believe”, "potential,” "expect”, "target”, "may” and "will” and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in research and development, including in relation to safety of drug candidates, cost of, progression of, and results from, our ongoing and planned clinical trials, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic candidates, potential commercial success of elafibranor if approved, exchange rate fluctuations, and our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company’s public filings with the AMF, including those listed in Chapter 2 "Risk Factors and Internal Control" of the Company's 2023 Universal Registration Document filed on April 5, 2024 (no. D.24-0246) with the Autorité des marchés financiers ("AMF"), which is available on GENFIT's website (www.genfit.fr) and the AMF's website (www.amf.org), and those discussed in the public documents and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company’s 2023 Annual Report on Form 20-F filed with the SEC on April 5, 2024 and subsequent filings and reports filed with the AMF or SEC or otherwise made public, by the Company. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.

CONTACTS

GENFIT | Investors

Tel: +33 3 2016 4000 | investors@genfit.com

PRESS RELATIONS | Media

Stephanie Boyer – Press relations | Tel: +333 2016 4000 | stephanie.boyer@genfit.com

GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com   

APPENDIX
H2 2024

	Buy side			Sell side
Date	Number of executions	Number of shares	Traded amounts in EUR	Number of executions	Number of shares	Traded amounts in EUR
TOTAL	2 752	2 075 591	8 893 798,52	2 582	1 999 091	8 546 873,15
01/07/2024	6	2001	7 303,53	27	23 000	84 574,91
02/07/2024	22	24486	90 640,07	29	35 435	132 089,99
03/07/2024	27	30939	114 380,86	33	71 378	267 007,25
04/07/2024	11	13001	51 663,89	42	51 221	201 406,61
05/07/2024	76	130000	511 275,70	57	61 233	244 186,18
08/07/2024	41	38897	151 285,60	55	77 768	305 129,75
09/07/2024	37	43587	176 002,45	9	12928	52712,47
10/07/2024	25	19013	74 870,39	17	29 144	116 282,19
11/07/2024	14	19855	79 675,90	24	34 636	140 647,14
12/07/2024	54	39000	159 246,75	12	15 601	63 635,70
15/07/2024	22	30425	125 035,49	26	27 840	115 579,99
16/07/2024	24	17501	72 881,51	23	29 825	123 879,63
17/07/2024	41	24001	100 374,10	13	13 463	56 731,20
18/07/2024	27	27001	113 194,13	24	21 843	91 658,25
19/07/2024	64	80377	325 742,26	14	4 701	19 124,19
22/07/2024	18	11578	47 447,92	40	41 101	167 583,98
23/07/2024	31	22655	90 992,22	12	4 466	18 016,60
24/07/2024	46	31000	123 816,48	27	29 786	118 749,93
25/07/2024	17	15068	59 955,12	36	24 916	100 006,84
26/07/2024	37	47001	191 976,99	28	29 289	120 740,39
29/07/2024	16	17454	71 026,43	40	28 266	115 827,28
30/07/2024	10	6022	24 353,81	8	3 907	15 902,90
31/07/2024	32	12888	51 668,12	9	3 003	12 178,31
01/08/2024	25	5485	22 139,98	12	9 901	40 186,97
02/08/2024	23	16442	63 462,01	3	3 026	11 609,37
05/08/2024	37	30384	110 456,47	34	29 384	106 272,82
06/08/2024	4	2501	9 253,65	7	12 501	46 653,61
07/08/2024	8	7501	28 378,83	9	8 417	32 071,21
08/08/2024	7	5001	18 853,77	1	1	3,8
09/08/2024	10	13417	50 264,64	7	7 501	28 553,76
12/08/2024	2	2501	9 228,72	7	8 001	29 858,69
13/08/2024	29	9212	34 354,50	15	13 123	49 281,59
14/08/2024	23	15001	57 091,26	24	21 585	82 604,72
15/08/2024	25	11739	44 362,74	30	15 805	60 242,34
16/08/2024	6	5790	22 426,58	26	24 328	95 234,63
19/08/2024	15	13592	52 667,91	18	6 059	23 525,58
20/08/2024	4	3435	13 433,94	17	14 935	58 413,47
21/08/2024	9	6567	25 786,31	26	24 001	95 280,85
22/08/2024	15	20001	78 653,93	8	5 231	20 573,68
23/08/2024	11	7501	29 241,37	15	12 271	48 021,70
26/08/2024	16	7174	28 039,51	8	3 501	13 766,46
27/08/2024	27	8828	34 423,37	6	3 501	13 766,42
28/08/2024	41	20771	80 264,34	13	7 271	28 326,29
29/08/2024	5	5001	19 053,81	13	16 290	62 948,96
30/08/2024	6	10001	38 928,89	26	14 068	55 202,97
02/09/2024	29	25251	96 750,22	1	1	3,93
03/09/2024	13	8751	32 474,96	6	3 501	13 102,46
04/09/2024	13	5251	19 489,93	20	15 427	58 046,71
05/09/2024	2	2501	9 678,87	24	14 255	55 482,46
06/09/2024	13	16251	62 303,90	10	3 501	13 443,91
09/09/2024	8	5251	19 734,99	15	7 033	26 505,62
10/09/2024	15	9151	34 604,32	9	5 278	20 074,19
11/09/2024	45	17567	65 787,54	12	12 494	47 053,78
12/09/2024	32	18185	68 250,12	27	19 859	75 053,32
13/09/2024	1	1	3,78	7	5 458	20 867,30
16/09/2024	11	4715	18 024,88	12	5 963	22 952,66
17/09/2024	22	9798	38 160,96	20	11 638	45 705,92
18/09/2024	7	2891	11 242,72	30	11 951	46 862,98
19/09/2024	13	7412	29 095,73	29	4 922	19 504,46
20/09/2024	5	3910	15 293,14	23	22 249	88 877,64
23/09/2024	13	13858	59 912,57	54	29 370	130 596,64
24/09/2024	15	10710	48 559,57	27	19 208	88 580,96
25/09/2024	14	8759	42 771,16	50	20 624	101 289,83
26/09/2024	11	10501	51 814,98	63	25 501	127 867,37
27/09/2024	6	6971	35 007,46	24	10 596	54 050,09
30/09/2024	11	4053	21 745,44	38	19 983	107 536,52
01/10/2024	60	42585	210 712,71	34	11 774	58 595,55
02/10/2024	3	2001	9 204,62	21	12 882	61 182,93
03/10/2024	8	4207	20 123,30	8	6 207	30 091,54
04/10/2024	9	5001	24 044,81	22	7 001	33 809,79
07/10/2024	20	7001	34 599,85	46	25 501	128 064,75
08/10/2024	30	13251	66 620,07	17	12 751	64 737,59
09/10/2024	18	5501	27 689,34	9	4 501	23 195,09
10/10/2024	3	2238	11 375,55	8	6 001	30 625,02
11/10/2024	15	6764	34 894,60	26	16 198	84 992,53
14/10/2024	20	11160	59 215,07	26	11 963	64 907,77
15/10/2024	27	17001	92 415,40	18	12 124	66 884,35
16/10/2024	18	10914	60 193,77	31	15 791	87 314,91
17/10/2024	14	9001	50 805,69	7	4 001	22 930,65
18/10/2024	36	25565	139 182,51	11	5 565	31 177,58
21/10/2024	31	16882	89 106,07	30	21 870	118 167,77
22/10/2024	22	9000	47 844,36	16	6 201	33 145,40
23/10/2024	37	23932	125 567,85	30	13 168	70 111,57
24/10/2024	43	30988	156 327,95	36	31 244	160 041,14
25/10/2024	19	11001	55 485,08	14	13 001	66 045,08
28/10/2024	10	9001	45 885,12	19	11 323	58 423,06
29/10/2024	2	1001	5 185,16	16	12 634	66 108,54
30/10/2024	4	2001	10 645,24	14	19 890	106 140,60
31/10/2024	34	18226	94 774,11	2	701	3 659,30
01/11/2024	27	8036	42 663,12	15	15 036	79 710,20
04/11/2024	42	35761	195 402,75	34	35 800	196 510,85
05/11/2024	38	33863	184 184,92	17	13 501	74 790,41
06/11/2024	56	54305	292 235,30	43	38 135	207 836,51
07/11/2024	23	23401	124 309,86	25	22 301	118 867,90
08/11/2024	50	76868	398 610,54	13	11 759	61 651,97
11/11/2024	6	2969	14 417,58	26	15 671	76 881,93
12/11/2024	16	10088	48 956,26	28	14 520	71 089,19
13/11/2024	22	7692	36 895,06	15	7 692	37 089,59
14/11/2024	60	32033	145 087,39	14	12 601	58 182,72
15/11/2024	36	21201	91 549,31	12	11 178	48 835,68
18/11/2024	42	25001	104 141,17	36	25 001	104 706,69
19/11/2024	23	14802	60 890,25	18	15 801	65 392,12
20/11/2024	23	19100	77 895,91	12	8 001	32 926,68
21/11/2024	26	17378	69 880,24	28	13 501	54 478,83
22/11/2024	42	16500	66 578,66	11	10 300	41 866,00
25/11/2024	19	17700	71 766,60	13	15 925	64 981,48
26/11/2024	22	17901	72 116,15	13	9 876	40 027,43
27/11/2024	16	10121	39 965,10	7	7 121	28 281,76
28/11/2024	23	13501	53 269,01	5	6 001	23 801,47
29/11/2024	27	15200	59 243,52	16	15 177	59 524,65
02/12/2024	33	22455	85 668,07	40	27 955	106 420,49
03/12/2024	22	18001	67 691,32	8	6 057	23 048,94
04/12/2024	15	12140	45 245,90	15	16 501	62 058,78
05/12/2024	32	27001	99 926,38	11	9 001	33 513,78
06/12/2024	6	3002	11 017,31	11	9 001	33 176,16
09/12/2024	10	9394	34 514,97	15	14 501	53 748,68
10/12/2024	15	11001	40 468,72	2	609	2 283,75
11/12/2024	20	15109	54 200,67	7	5 001	18 353,67
12/12/2024	3	3001	10 623,57	12	8 609	30 790,52
13/12/2024	9	6030	21 458,18	8	5 893	21 185,87
16/12/2024	7	4472	15 688,94	8	9 001	31 961,02
17/12/2024	37	19501	67 968,59	7	3 098	10 687,23
18/12/2024	4	1501	5 103,45	29	17 904	62 399,74
19/12/2024	1	1	3,51	10	5 001	17 751,00
20/12/2024	32	20501	70 673,51	52	20 501	70 401,66
23/12/2024	5	6001	20 643,44	8	6 001	20 793,47
24/12/2024	1	1	3,47	4	1 501	5 215,98
27/12/2024	1	1	3,5	3	5 001	17 503,50
30/12/2024	20	11500	40 647,56	18	9 091	32 235,32
31/12/2024	12	4002	14 007,04	21	7 411	26 046,70

   

---

1 Elafibranor is marketed and commercialized in the U.S by Ipsen under the trademark Iqirvo®.

Attachment

• GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial